Can Polycythemia Vera Be Cured?

Polycythemia vera (PV) has no conventional cure for the vast majority of people who live with it. The single exception is an allogeneic stem cell transplant, which can eliminate the disease but carries serious risks and is reserved almost exclusively for patients whose PV has progressed to a more dangerous phase. For everyone else, the realistic goal is long-term control: keeping blood counts in a safe range, preventing blood clots, and managing symptoms. The good news is that newer therapies are showing they can push back against the underlying genetic driver of PV in ways older treatments never could, raising questions about whether something approaching a functional cure might eventually be within reach.

What Drives PV at the Molecular Level

PV is classified as a myeloproliferative neoplasm, a type of slow-growing blood cancer. The root cause in almost all cases is a mutation in the JAK2 gene. The specific mutation, called V617F, shows up in roughly 97% of PV patients and acts like a stuck accelerator pedal on the signaling pathway that tells the bone marrow to produce red blood cells.¹ The result is an overproduction of red blood cells, which thickens the blood and dramatically raises the risk of clots, strokes, and heart attacks. A small minority of patients carry a different JAK2 mutation in exon 12, but the downstream effect is similar.

Because PV stems from a single acquired genetic change in the blood-forming stem cells, curing the disease in theory would mean eliminating all the cells carrying that mutation, or at least reducing them to an undetectable level. That is an extraordinarily difficult goal when the mutant clone has already established itself in the bone marrow.

How Treatment Keeps PV Under Control

The foundation of PV management for decades has been phlebotomy, the deliberate removal of blood to bring down red blood cell counts. The target is to keep hematocrit, the percentage of blood volume occupied by red cells, below 45%. A landmark randomized trial showed why this number matters: patients managed to a hematocrit below 45% had far fewer cardiovascular events than those allowed to run higher, with the higher-hematocrit group experiencing roughly four times the rate of clots and related problems.² That trial cemented 45% as the therapeutic line in the sand.

For patients who need more than phlebotomy alone, hydroxyurea has long been the standard first-line drug. It works by broadly suppressing the bone marrow’s production of blood cells. A systematic review and meta-analysis of clinical outcomes under hydroxyurea found an average annual thrombosis rate of about 3.3%, ranging from under 2% per year in younger patients with no prior clots to nearly 7% per year in older patients.³ Hydroxyurea is effective at controlling blood counts, but it does not target the JAK2-mutant clone specifically, so it does not move the disease toward anything resembling a cure. Patients who remain dependent on frequent phlebotomies even while on hydroxyurea face worse outcomes: one study found that needing three or more phlebotomies per year on top of hydroxyurea was associated with a thrombosis rate of about 20% over three years, compared to roughly 5% in patients who needed fewer.⁴

Important as these therapies are, they manage the consequences of PV rather than attacking its cause. They do not shrink the population of mutant cells in the marrow. That distinction becomes critical when we ask whether any current treatment can genuinely change the disease’s trajectory.

Interferon and the Push Toward Disease Modification

The most promising candidate for something beyond mere disease control is interferon alpha, specifically a newer pegylated formulation called ropeginterferon alfa-2b. Unlike hydroxyurea, interferon appears to preferentially target the JAK2-mutant stem cells, gradually reducing their share of the bone marrow. Researchers track this by measuring the JAK2 V617F allele burden, essentially the percentage of blood-forming cells carrying the mutation.

A meta-analysis of ropeginterferon alfa-2b studies found a significant average reduction in JAK2 allele burden, with about one in four patients achieving a formal molecular response.⁵ In a smaller study following patients who achieved a durable complete hematologic response, the average JAK2 allele burden dropped from over 43% at baseline to under 13%, with about 85% of those patients reaching a partial molecular response and two patients (about 15%) reaching a complete molecular response, meaning the mutation became undetectable.⁶

Those complete molecular responses are tantalizing, but they are rare and require years of sustained treatment. It remains unclear whether driving the mutant clone below detection means it is truly gone or merely hiding at very low levels. Emerging data suggest that starting interferon earlier in the disease course may improve molecular response rates and could someday enable time-limited therapy, where patients treat for a defined period and then stop.⁷ But longer follow-up is still needed to confirm whether molecular responses translate into fewer clots, less progression, and longer survival. For now, calling interferon a “cure” would be premature, though it is the closest thing to disease modification available outside a transplant.

There is also a practical barrier: cost. A cost-effectiveness analysis estimated that ropeginterferon alfa-2b provided about 0.4 additional quality-adjusted life years compared with hydroxyurea at an added cost of roughly $60,000, yielding a cost per quality-adjusted life year of about $142,000.⁸ Whether that figure represents good value depends heavily on the healthcare system and the individual patient’s priorities, but it puts the drug well above the cost thresholds many insurers consider easily justifiable.

Ruxolitinib for Resistant or Intolerant Disease

Ruxolitinib is a JAK1/JAK2 inhibitor, meaning it directly blocks the overactive signaling pathway that the JAK2 mutation turns on. It earned approval for PV patients who don’t respond well to hydroxyurea or can’t tolerate its side effects. In the pivotal RESPONSE trial, ruxolitinib proved superior to the best available alternative therapy at controlling hematocrit, shrinking enlarged spleens, and relieving symptoms like severe itching.⁹ The degree of spleen enlargement at baseline did not significantly affect whether patients achieved hematocrit control.¹⁰

Ruxolitinib is an effective symptom controller, but it does not appear to meaningfully reduce the JAK2 allele burden the way interferon can. It treats the symptoms and consequences of the overactive pathway without eliminating the mutant cells that create the problem. Think of it as quieting the alarm rather than putting out the fire. That makes it valuable, especially for patients with significant symptom burden or splenomegaly, but it does not move the needle toward cure.

Stem Cell Transplant as the Only Potential Cure

Allogeneic hematopoietic stem cell transplant, where a patient’s bone marrow is replaced with donor marrow, is the only treatment recognized as potentially curative for PV.¹¹ The word “potentially” is doing a lot of work in that sentence. The procedure replaces the patient’s mutant marrow entirely, which in principle removes the disease at its source. But it comes with substantial treatment-related mortality and toxicity.¹²

Because PV in its chronic phase is a manageable condition with a long life expectancy, the risk-benefit math of transplant simply doesn’t add up for most patients. The procedure is generally considered only when PV has progressed to myelofibrosis (where the bone marrow becomes scarred and dysfunctional) or to acute myeloid leukemia. At that point, the disease has become life-threatening enough that the high risks of transplant become acceptable. For someone living with stable, well-controlled PV, no responsible hematologist would recommend a transplant.

The Risk of Disease Progression

The possibility that PV will evolve into something more dangerous is one of the chief concerns in long-term management. PV can progress to myelofibrosis or, less commonly, to acute myeloid leukemia. A study examining leukemic transformation found that genomic profiles could help predict how quickly this might happen, with median times to transformation ranging from 3 years in a high-risk group to 21 years in a low-risk group.¹³ For the highest-risk patients, nearly all transformations occurred within five years of diagnosis, while the lowest-risk group saw no transformations within the first twelve years.

Understanding these risk categories matters because progression to myelofibrosis or leukemia is the scenario where stem cell transplant enters the conversation. It is also the scenario where survival drops substantially. The goal of all the treatments discussed, from phlebotomy to interferon, is partly to delay or prevent this progression, though definitive proof that any drug reduces transformation risk is still accumulating.

Survival and What “Well-Managed” Looks Like

Survival in PV varies enormously depending on how the disease is managed. A population-based study of 327 patients found that relative survival (compared to people of the same age and sex in the general population) was about 93% at five years but dropped to roughly 46% at twenty years, with relative survival reaching 50% at about 17 years after diagnosis.¹⁴ Those numbers reflect a mix of patients with varying levels of treatment optimization.

A separate analysis compared PV patients in a national cancer registry (representing the broader population) with patients at a specialized academic center. The registry patients had significantly higher mortality than expected, but the academic center patients had overall survival that was not statistically different from the general population, suggesting that expert management can close much of the survival gap.¹⁵ The catch: even in that well-managed group, excess mortality began to appear after about 17 years, driven largely by myelofibrosis progression, which affected nearly half of PV patients after 25 years of follow-up. So good management can give you a near-normal lifespan for many years, but the disease’s tendency to evolve eventually catches up with a substantial fraction of patients.

Newer Therapies on the Horizon

Beyond interferon and ruxolitinib, several experimental approaches are in various stages of testing. The one closest to the finish line is rusfertide, a hepcidin mimetic. Hepcidin is the body’s master regulator of iron availability, and by mimicking it, rusfertide restricts the iron supply that the overactive bone marrow needs to churn out red blood cells. The approach is mechanistically different from anything else in the PV toolkit: rather than suppressing the marrow broadly or blocking JAK signaling, it starves the red-cell production line of a key raw material.

Results from the phase 2 REVIVE study were striking. Patients who had been averaging roughly 8.5 phlebotomies per year before enrollment dropped to fewer than one per year on rusfertide, and hematocrit stayed consistently below 45%.¹⁶ In the randomized portion of the study, 60% of patients on rusfertide met the response criteria compared to 17% on placebo.¹⁷ Two-year follow-up data showed that patients remained essentially phlebotomy-free as long as they continued the drug, with stable hematocrit control.¹⁸

Rusfertide does not target the JAK2 clone and is not expected to produce molecular responses, so it would not move toward cure in the way interferon might. Its value lies in freeing patients from the burden of repeated phlebotomies and maintaining tighter hematocrit control. Other experimental classes under investigation include MDM2 inhibitors, histone deacetylase inhibitors, and LSD1 inhibitors, all aimed at correcting the abnormal blood cell production through different mechanisms.¹⁹ Whether any of these will prove capable of eliminating the mutant clone remains to be seen.

The Symptom Burden People Don’t Talk About

Discussions of cure and survival sometimes overshadow what daily life with PV actually feels like. PV patients consistently report a higher symptom burden than the general population, with measurable impacts on their quality of life and daily functioning.²⁰ Among the myeloproliferative neoplasms, PV patients actually report the worst quality of life at diagnosis, with fatigue as the single most common complaint, followed by inactivity, dizziness, itching, and depression.²¹

The itching deserves special mention because it is one of the most distinctive and distressing features of PV. Aquagenic pruritus, itching triggered by contact with water, is a hallmark symptom. A study of 441 PV patients found that about 15% described their pruritus as “unbearable,” and those patients reported reduced overall health and higher levels of fatigue, pain, and breathing difficulties.²² Imagine dreading a shower because it reliably triggers intense, whole-body itching that can last for hours. Ruxolitinib and interferon both show some benefit for pruritus, but for many patients, this symptom remains difficult to fully control. When people with PV ask about a cure, they are often thinking as much about the grinding daily symptoms as about the long-term cancer risks.

PV During Pregnancy

PV in pregnancy is an uncommon but high-stakes situation. The disease’s tendency to thicken blood and promote clotting adds risk on top of the already pro-coagulant state that pregnancy itself creates. Antiplatelet therapy and close monitoring by both a hematologist and an obstetrician are considered essential. Many of the standard PV drugs, including hydroxyurea and ruxolitinib, are not safe during pregnancy, which limits options mostly to phlebotomy, low-dose aspirin, and in some cases interferon.²³ With careful management, good outcomes for both mother and baby are achievable, but the situation demands a coordinated team and vigilant surveillance throughout pregnancy and the postpartum period.